Overview of the disease burden of invasive pneumococcal disease in Asia-Reference-Cited by-同舟云学术

Overview of the disease burden of invasive pneumococcal disease in Asia

Published:2009-12 Issue:52 Volume:27 Page:7282-7291
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Bravo L.C.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference68 articles.

1. Pneumococcal conjugate vaccine for childhood immunization. March 2007 WHO Position Paper;World Health Organization;Wkly Epidemiol Record,2007

2. The preventable burden of pneumococcal disease in the developing world;Scott;Vaccine,2007

3. Plan Asia. Growing up in Asia: Plan's strategic framework for fighting child poverty in Asia 2005–2015. Bangkok: Plan Ltd., 2005. Available at: http://www.plan-international.org/pdfs/growingupinasia.pdf. Accessed 8 July 2008.

4. World Health Organization. World health statistics 2008. Geneva: WHO; 2008. Available at: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf. Accessed 30 July 2008.

5. WHO global burden of Hib and pneumococcal disease in children;Knoll,2007

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study;Vaccine;2024-05

2. Retrospective database analysis for clinical diagnoses commonly associated with pneumococcal diseases in the Malaysian healthcare system over a 3-year period (2013–2015);BMC Infectious Diseases;2024-01-12

3. Immunogenicity and Safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14^TM) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study;2023-12-24

4. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult;Frontiers in Public Health;2023-06-29

5. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong;Human Vaccines & Immunotherapeutics;2022-04-14